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using both components of the EQ-5D: the ﬁve dimensions,
Mobility, Self-Care, Usual Activities, Pain, Anxiety/Depression
and their Tariff, and the Visual Analogue Scale. Also were col-
lected the answers to questions that previous studies found that
could be conditioning the satisfaction, sociodemographic, phar-
macological and clinical data. Nurses scored the functional
impairment of patients with the Karnofsky Performance Scale
and the Barthel Scale. RESULTS: Finally 128 patients, 65.6%
men, completed the interview. Mean age was 65.67  16.54 and
mean of months on dialysis was 28.47  44.50. SERVQHOS
Alfa’s reliability was 0.96.The satisfaction levels were similar to
those found in other haemodialysis units in Spain and higher in
the arranged health centre in 6 aspects (p < 0.05). Patients were
more satisﬁed with those aspects related with the kindness and
the disposal of the unit staff, and less satisﬁed with those related
with the facility to go to the unit and the punctuality of the
sessions. Lower satisfaction levels were related with worse self-
score of the health the day of the interview that the rest of the
year, time since starting dialysis, longer sessions, no dose of iron,
female gender, to have been transplanted previously, higher
haemoglobin and haematocrit levels and lower age (p < 0.05).
Otherwise, lower educational levels, less qualiﬁed jobs, a good
valuation of the ambulance to go to the unit, to think that
the renal illness and the dialysis is well explained, and mainly
that patient opinion is considered to treat the renal disease,
increased the satisfaction with the measured aspects (p < 0.05).
CONCLUSIONS: To identify those factors that are modulating
the satisfaction is as important as to measure it, since they
indicate what issues need to be enhanced in order to increase the
perception of the quality of the service. Also it must be consid-
ered that exist factors attached to patients, as socioeconomic
level, physical and mental status, and the own experience with
the illness that are inﬂuencing the perceived satisfaction. These
ﬁndings indicate that it seems necessary as well to leave the
paternalistic model and that clinicians should give patients more
information and autonomy in order to make decisions about the
illness, since the perception of the autonomy is associated with
patient satisfaction.









HEALTH CARE DECISION-MAKER’S CASE STUDY
POSTER SESSION
PCASE1
ESTABLISHMENT OF A COST-EFFECTIVENESS (CE)
THRESHOLD AT KING HUSSEIN CANCER CENTER:
IMATINIB IN CHRONIC MYELOGENOUS LEUKEMIA (CML)
Jabr MF,Treish IM
King Hussein Cancer Center, Amman, Amman, Jordan
Organization: Center for Drug Policy and Evaluation (CDPE),
Department of Pharmacy, King Hussein Cancer Center (KHCC).
Problem or Issue Addressed: Novel anti-cancer treatments are
typically accompanied with substantially higher acquisition
costs. The Government of Jordan, in dealing with healthcare
budgetary challenges, has not issued speciﬁc guidance on CE
threshold to manage the drug budget and for resource allocation.
Application of US/EU thresholds is not applicable to Jordan due
to differences in the scale of socioeconomic development. The
Pharmacy & Therapeutics committee (P&T) at KHCC has been
facing the sensitive task of evaluating and approving new expen-
sive anti-cancer therapies to the drug formulary. Economic evalu-
ation of newer versus existing therapies requires the setting of a
CE threshold or benchmark against which resulting incremental
cost-effectiveness ratios (ICERs) have to be compared and
weighed.
Goals: To establish of a CE threshold acceptable to the admin-
istration of KHCC and the P&T as the willingness-to-pay thresh-
old for each life year gained
Outcomes items used in the decision: Lifetime costs and survival
beneﬁts for CML patients taking imatinib (Glivec, Novartis,
Basel, Switzerland) will provide an acceptable cost per each life
year gained threshold.
Implementation Strategy: Imatinib is one of the most expensive
antineoplastics used in Jordan. Its use in chronic phase CML is
considered standard of care by the government due to its advan-
tageous efﬁcacy and safety proﬁle. Therefore, it is an ideal drug
to use in the modeling of CE thresholds. CDPE modeled the total
expenditure and survival beneﬁts of this therapy and used it to
establish an acceptable cost for each life year gained that the
institution and the payers are willing to pay. This threshold could
then be used as a benchmark when conducting CE studies for
future high cost drugs.
Results: The decision model produced the following results: The
mean estimated survival with ﬁrst-line imatinib therapy was
11.59 Life years. Undiscounted lifetime costs were approxi-
mately 500,690 USD with imatinib. Imatinib therefore provides
a threshold of approximately 43,164 USD/ Life years gained. The
proposed ﬁgure of 43,000 USD per life year gained as a cost-
effectiveness threshold at KHCC was approved by the Medical
Board and the P&T as it is reﬂective of the maximum payment
trends already present at KHCC.
Lessons Learned: This modeling study provided, for the ﬁrst time
within the Jordanian health care system, a benchmark for for-
mulary decision making which will be used to evaluate new
expensive antineoplastics. We hope this exercise will represent an
example that can be customized and implemented in other gov-
ernment and private healthcare institutions in Jordan and the
neighboring countries in the Middle East region.
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